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Abstract
Background: The burden of malaria remains high for children in parts of Africa despite the use of insecticide-
treated bed nets (ITNs). Chemoprevention has the potential of reducing the malaria burden; however, limited data
exist on the efficacy and safety of anti-malarial therapy in the setting of chemoprevention.
Methods: 600 children 4–5 months of age were enrolled in Tororo, Uganda, an area of high transmission intensity.
Participants were given ITNs, and caregivers instructed to bring their child to a study clinic whenever they were ill.
Starting at six months of age, 579 were randomized to no chemoprevention, monthly sulphadoxine-pyrimethamine
(SP), daily trimethoprim-sulphamethoxazole (TS), or monthly dihydroartemisinin-piperaquine (DP). Study drugs were
administered unsupervised at home until 24 months of age. Episodes of uncomplicated malaria were treated with
artemether-lumefantrine (AL) with active follow-up for 28 days. The cumulative risk of recurrent malaria within
84 days and the risk of adverse events within 28 days were compared across study arms using a Cox proportional
hazards model and generalized estimating equations, respectively.
Results: A total of 1007, 919, 736, and 451 episodes of malaria were treated in the no chemoprevention, SP, TS,
and DP arms, respectively. Only 19 (0.6%) treatments were for severe malaria. Early response to therapy with AL
was excellent with 96.5% fever clearance and 99.4% parasite clearance by day 3. However, over 50% of AL
treatments were followed by recurrent parasitaemia within 28 days. Compared to the no chemoprevention arm,
the cumulative risk of recurrent malaria within 84 days following treatment of uncomplicated malaria with AL was
significantly lower in the DP arm (HR = 0.77, 95% CI 0.63-0.95, p = 0.01) but not the SP or TS arms. Compared to the
no chemoprevention arm, none of the chemopreventive regimens were associated with an increased risk of
adverse events following treatment of malaria with AL.
Conclusions: The risk of severe malaria was very low in this cohort of young children living in a high transmission
setting. In the setting of chemoprevention, treatment of uncomplicated malaria with AL was safe and efficacious,
with moderate protection against recurrent malaria among children assigned monthly DP.
Trial registration: ClinicalTrials.gov NCT00948896.
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Background
The burden of malaria remains unacceptably high in
some parts of sub-Saharan Africa despite the scaling up of
control interventions including provision of insecticide-
treated bed nets (ITNs), indoor residual spraying of in-
secticide, and prompt malaria case management with
artemisinin-based combination therapy (ACT). In 2012,
there were an estimated 207 million cases and 627,000
deaths, with 80% of cases and 90% of deaths occurring in
Africa, primarily in children under five years of age
[1]. With such high morbidity and mortality, achieving
Millennium Development Goals 4 and 6 by 2015 will
be unlikely without additional control measures, espe-
cially in areas of Africa with persistent high malaria
transmission intensity.
The use of anti-malarial drugs for the prevention of
malaria in children at high risk has recently received
widespread attention as an alternative control strategy.
Intermittent preventive therapy in infants (IPTi) with
sulphadoxine-pyrimethamine (SP) at the time of routine
vaccinations has been recommended by the WHO in
certain settings [1]. Alternatively, seasonal malaria che-
moprevention (SMC) at monthly intervals generally with
combination of SP plus amodiaquine has been recom-
mended by the WHO is parts of West Africa where mal-
aria transmission is primarily limited to a few months
during the year [1]. However, alternative drugs and/or
approaches are needed in areas where the prevalence of
resistance to antifolate drugs is high or malaria transmis-
sion occurs throughout the year.
Two parallel randomized control trials were recently
completed in cohorts of HIV-unexposed (born to HIV
uninfected mothers) and HIV-exposed (born to HIV in-
fected mothers) children aged 6–24 months living in an
area of Uganda with high antifolate resistance and in-
tense, year-round transmission [2,3]. Children were
randomized to no chemoprevention, monthly SP, daily
trimethoprim-sulphamethoxazole (TS), or monthly
dihydroartemisinin-piperaquine (DP) for the preven-
tion of malaria. In these trials, monthly DP was highly
effective, daily TS moderately effective, and monthly
SP provided no significant protection against malaria.
In all three treatment arms the burden of uncompli-
cated malaria remained substantial, requiring frequent
treatment with artemether-lumefantrine (AL), the current
first-line therapy for uncomplicated malaria in Uganda
and many other African countries. The treatment of mal-
aria in the setting of various chemopreventive regimens
raises questions regarding the safety and efficacy of AL
when other concomitant anti-malarial drugs are being
used. In this report, initial response to therapy, the risk of
recurrent parasitaemia and recurrent malaria, and the risk
of adverse events following the treatment of uncompli-
cated malaria with AL were compared among children
not taking chemoprevention with children taking three
different chemoprevention regimens.
Methods
Study design, site and population
Two parallel, open label, randomized control trials of
malaria chemoprevention were conducted in Tororo,
Eastern Uganda, an area with intense year-round malaria
transmission and an entomological inoculation rate
(EIR) estimated at 125 infectious bites per person-year
in 2011–12 [4]. Details of the parent clinical trials have
been reported [2,3]. Briefly, convenience sampling was
used to enroll 600 infants “(400 HIV-exposed, 200 HIV-
exposed)” 4–5 months of age from the Tororo District
Hospital antenatal clinic between June 2010 and July
2011 (Figure 1). At enrollment each household was
given two long-lasting ITNs. Study participants were ran-
domized to one of four chemoprevention arms: no chemo-
prevention, TS (Co-trimoxazole, Kampala Pharmaceutical
Industries, Uganda) single dose once daily, SP (Kamsidar,
Kampala Pharmaceutical Industries, Uganda) single dose
each month, and DP (Duo-Cotexin, Holley-Cotec, Beijing,
China) once daily for three consecutive days each month.
HIV-unexposed children were randomized at six months of
age and the HIV-exposed were randomized after cessation
of breastfeeding and confirmation of their HIV-negative
status (median age 10 months). Chemoprevention drugs
were administered unsupervised at home according to
weight-based guidelines.
Study procedures
The purpose of this report was to evaluate the safety
and efficacy of treatment for malaria in the context of
chemoprevention. Participants received all of their
medical care at a designated study clinic open every
day. Parents/guardians were encouraged to bring their
children to the clinic any time they were ill. Children
who presented with a documented fever (tympanic
temperature ≥38.0°C) or history of fever in the previ-
ous 24 hours had blood obtained by finger prick for a
thick blood smear. If the smear was positive, the pa-
tient was diagnosed with malaria and a complete
blood count (CBC) and thin blood smear for parasite
speciation were performed. Episodes of uncomplicated
malaria were treated with artemether-lumefantrine
(AL), the recommended first-line treatment in Uganda.
AL was administered twice a day for 3 days, with the first
daily dose given with milk and under direct observation in
the clinic. The second daily dose was administered at
home. Mothers were encouraged to give the second dose
with milk or after a meal. Episodes of complicated malaria
(severe malaria or danger signs) [5] or treatment failures
occurring within 14 days of prior therapy were treated
with quinine. All episodes of malaria were actively
Kapisi et al. Malaria Journal  (2015) 14:53 Page 2 of 10
followed on days 1, 2, 3, 7, 14, 21, and 28 following
the diagnosis with repeat thick blood smears on all
follow-up days except day 1 and repeat haemoglobin
measurement on day 28 or the day of clinical failure.
At each follow-up visit study clinicians assessed pa-
tients for adverse events according to standardized cri-
teria based on National Institutes of Health guidelines.
Serious adverse events were defined as experiences
resulting in death, life-threatening experience, inpatient
hospitalization, persistent or significant incapacity, or
medical or surgical intervention to prevent serious out-
comes. Following 28-day active surveillance, children were
followed passively until their next diagnosis of malaria or
the end of the study. Study participants were followed
until they reached 24 months of age or were prematurely
withdrawn from the study for any of the following: 1)
movement out of the study area, 2) failure to be seen in
the study clinic for >60 consecutive days, 3) withdrawal of
informed consent, or 4) inability to comply with the study
schedule and procedures.
Laboratory procedures
Thick and thin blood smears were stained with 2%
Giemsa for 30 minutes. Parasite density was estimated
by counting the number of asexual parasites per 200
white blood cells and assuming a white blood cell count
of 8,000 per μL. A thick smear was deemed negative if
no parasites were seen in 100 high powered fields. Thin
smears were used for species identification. Microscopy
quality control included re-reading all blood smears and
resolution of any discrepancies by a third microscopist.
Haemoglobin levels were measured using a Beckham
coulter counter machine or a portable spectrophotom-
eter (HemoCue, Ängelholm, Sweden). Piperaquine (PQ)
drug levels were measured from capillary blood collected
on filter paper on the day malaria was diagnosed among
study participants randomized to monthly DP, as previ-
ously described [2].
Statistical methods
Data were double-entered and verified in Microsoft
Access and statistical analyses performed using Stata,
version 12 (Stata-Corp). Efficacy and safety outcomes
were assessed at the level of each treatment of uncom-
plicated malaria with AL. 28-day efficacy outcomes in-
cluded fever and parasite clearance by day 3, appearance
of gametocytes not present on day 0, haemoglobin re-
covery, and WHO treatment outcomes using a standard-
ized classification system [5]. 28-day safety outcomes
were based on the identification of adverse events not
present on day 0 or of increased severity compared to
day 0. These outcomes were compared between the no
chemoprevention arm and each of the three chemopre-
vention regimens using generalized estimating equations
with adjustment for repeated measures in the same pa-
tient. Cumulative risks of recurrent malaria within
84 days were estimated using the Kaplan-Meier product
limit formula with data censored for patients who did
not complete follow-up. Univariate and multivariate ana-
lyses of risk factors associated with recurrent malaria
were made using Cox proportional hazards models with
adjustment for repeated measures in the same patient.
Risk factors for recurrent malaria of interest included
the assigned chemoprevention arm, household wealth
index [6], area of residence, age, pre-treatment parasite
density, gender, HIV exposure status for all children, and
PQ drug levels on the day malaria was diagnosed for
Figure 1 Study profile. SP = sulphadoxine-pyrimethamine, TS = trimethoprim-sulphamethoxazole, DP = dihydroartemisinin-piperaquine,
AL = artemether-lumefantrine.
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children randomized to monthly DP. A p value of <0.05
was considered statistically significant.
Ethical approval
Ethical approval was obtained from the Uganda National
Council for Science and Technology, the Makerere Univer-
sity School of Medicine Research and Ethics Committee,
and the University of California, San Francisco Committee
on Human Research.
Results
Study profile and characteristics of the malaria episodes
A total of 579 (393 HIV-unexposed and 186 HIV-
exposed) children were randomized to one of the four
chemoprevention arms and 514 (340 HIV-unexposed
and 174 HIV-exposed) were followed up to 24 months
of age (Figure 1). A total of 3,113 treatments for malaria
were given across all 4 arms (97.0% due to P. falcip-
arum) of which 3,058 (98.2%) were treated with AL and
55 were treated with quinine (Figure 1). Indications for
quinine treatment included 20 with danger signs without
meeting criteria for severe malaria, 19 with severe mal-
aria (15 severe anaemia, three multiple convulsions, one
respiratory distress), and 16 with recurrent uncompli-
cated malaria within 14 days of treatment with AL. Base-
line characteristics of all episodes of uncomplicated
malaria treated with AL stratified by chemoprevention
arm are presented in Table 1. Compared to the no che-
moprevention arm, children with uncomplicated malaria
in the TS and DP chemoprevention arms were signifi-
cantly older and more likely to be in the lowest tertile of
household wealth. Compared to the no chemopreven-
tion arm, children with uncomplicated malaria in the TS
chemoprevention arm had significantly lower parasite
densities and higher prevalence of gametocytes (Table 1).
There were no significant differences across the 4
chemoprevention arms in gender, location of residence,
HIV-exposure status, temperature, or haemoglobin levels.
Over 95% of parents/guardians reported giving the last
assigned dose of chemoprevention drug prior to episodes
of uncomplicated malaria being diagnosed.
Efficacy outcomes
Early response to therapy with AL was excellent across
all four chemoprevention arms. There were no signifi-
cant differences in fever clearance across the chemopre-
vention arms with over 96% of children afebrile by day
3. There were no significant differences in parasite clear-
ance across the chemoprevention arms with over 92% of
blood smears negative by day 2 and over 99% negative
by day 3 (Table 2). Only 16 (0.5%) of AL treatments re-
sulted in early treatment failures; 14 developed criteria
for severe malaria or dangers signs within 2 days of initi-
ation of AL and 2 had a positive blood smear and fever
on day 3. Despite excellent early response to AL therapy,
43.5% of episodes developed recurrent parasitaemia
within 28 days of follow-up with no significant differ-
ences across the chemoprevention arms. There were no
Table 1 Baseline characteristics of all episodes of uncomplicated falciparum malaria treated with AL
Characteristic Chemoprevention arm
No
chemoprevention
Monthly Daily Monthly
SP TS DP
Number of episodes 992 901 721 444
Patient age in months, mean (SD) 16.0 (5.1) 16.1 (5.1) 16.9 (4.8)b 17.8 (4.5)b
Female gender, n (%) 428 (43.2%) 407 (45.2%) 344 (47.7%) 211 (47.5%)
Urban residence, n (%) 13 (1.3%) 26 (2.9%) 14 (1.9%) 18 (4.1%)
Household wealth index, n (%)
Lowest tertile 319 (32.2%) 284 (31.5%) 308 (42.7%)b 176 (39.6%)b
Middle tertile 381 (38.4%) 347 (38.5%) 236 (32.7%) 149 (33.6%)
Highest tertile 292 (29.4%) 270 (30.0%) 177 (24.6%) 119 (26.8%)
HIV-exposeda, n (%) 235 (23.7%) 179 (19.9%) 114 (15.8%) 81 (18.2%)
Temperature °C, mean (SD) 38.0 (1.0) 37.9 (1.0) 37.9 (1.0) 37.9 (1.0)
Parasite density per μL, geometric mean 16321 15257 11702b 16841
Gametocytes present, n (%) 41 (4.1%) 34 (3.8%) 48 (6.7%)b 11 (2.5%)
Haemoglobin g/dL, mean (SD) 9.7 (1.3) 9.6 (1.4) 9.8 (1.3) 9.9 (1.2)
Days since last dose of chemopreventive drug assigned, median (IQR) N/A 17 (10–24) 1 (1–1) 16 (8–23)
Proportion of prior dose of chemopreventive drug reported taken N/A 95.5% 98.6% 96.0%
aHIV-uninfected children born to HIV-infected mothers.
bp-value < 0.05 when compared to no chemoprevention arm.
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significant differences in the appearance of gametocytes
or haemoglobin recovery across the chemoprevention
arms (Table 2).
When follow-up was extended to 84 days following
treatment with AL, the cumulative risk of recurrent mal-
aria ranged from 72.2% in the DP chemoprevention arm
to 81.0% in the no chemoprevention arm (Figure 2). In
multivariate analyses, being assigned to the DP chemo-
prevention arm was associated with a 23% reduction in
the hazard of recurrent malaria compared to the no che-
moprevention arm (HR = 0.77, 95% CI 0.63-0.95, p =
0.01). There were no significant differences in the hazard
Table 2 Efficacy outcomes after 28 days of follow-up
Efficacy outcomes Chemoprevention arm
No chemoprevention
(n = 992)
Monthly SP
(n = 901)
Daily TS
(n = 721)
Monthly DP
(n = 444)
Fever clearancea, n (%)
Fever present on day 1 497 (50.2%) 445 (49.5%) 339 (47.0%) 203 (46.1%)
Fever present on day 2 73 (7.4%) 87 (9.7%) 58 (8.1%) 32 (7.3%)
Fever present on day 3 37 (3.9%) 32 (3.7%) 20 (2.9%) 16 (3.8%)
Parasite clearance, n (%)
Positive blood smear on day 2 54 (5.5%) 51 (5.7%) 35 (4.9%) 24 (5.5%)
Positive blood smear on day 3 5 (0.5%) 4 (0.5%) 4 (0.6%) 6 (1.4%)
WHO treatment outcome, n (%)
No outcome 29 (2.9%) 25 (2.8%) 24 (3.3%) 16 (3.6%)
Early treatment failure 1 (0.1%) 8 (0.9%) 4 (0.6%) 3 (0.7%)
Late clinical failure 172 (17.3%) 148 (16.4%) 112 (15.5%) 71 (16.0%)
Late parasitological failure 284 (28.6%) 240 (26.6%) 190 (26.4%) 115 (25.9%)
Adequate clinical and parasitological response 506 (51.0%) 480 (53.3%) 391 (54.2%) 239 (53.8%)
Appearance of gametocytesb, n (%) 33 (3.5%) 33 (3.8%) 24 (3.6%) 16 (3.7%)
Haemoglobin recoveryc g/dL, mean (SD) 0.5 (1.3) 0.5 (1.2) 0.6 (1.2) 0.6 (1.1)
aSubjective fever over previous 24 hours or temperature ≥ 38.0°C.
bPatients with gametocytes present on day 0 not included.
cChange in haemoglobin from day 0 to day 28 or day of clinical failure.
Figure 2 Cumulative risk of recurrent malaria within 84 days of treatment with artemether-lumefantrine (AL) stratified by
chemoprevention arm.
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of recurrent malaria between the SP and TS chemopre-
vention arms compared to the no chemoprevention arm
(Table 3). Being in the highest tertile of the wealth index
was associated with a significantly lower hazard of recur-
rent malaria (HR = 0.78, 95% CI 0.66-0.92, p = 0.003),
while increasing age (HR = 1.19 per 6 month increase,
95% CI 1.12-1.26, p < 0.001) and higher pre-treatment
parasite density (HR = 1.05 per log10 increase, 95% CI
1.00-1.10, p = 0.04) were significantly associated with an
increased hazard of recurrent malaria (Table 3).
PQ levels were available on the day malaria was diag-
nosed for 425 of 444 (95.7%) episodes treated with AL
among children assigned to chemoprevention with
monthly DP. PQ levels were < 10 ng/mL on the day mal-
aria was diagnosed in 51.1% of episodes, suggesting that
a complete dose of DP was not administered in the pre-
vious month despite the fact that 96.0% of caregivers re-
ported administering the prior dose of DP [7]. There
was a strong relationsip between PQ levels at the time
malaria was diagnosed and the cumulative risk of recur-
rent malaria within 84 days following treatment with
AL; ranging from 83.5% among episodes with PQ below
the level of detection (<2.5 ng/ml) to 36.5% among epi-
sodes with PQ levels ≥ 50 ng/ml (Figure 3). Indeed, in
multivariate analysis, having a PQ level of ≥ 50 ng/ml
was associated with a 70% reduction in the hazard of re-
current malaria (HR = 0.30, 95% CI 0.14-0.63, p = 0.001)
compared to those with undetectable PQ levels (Table 4).
Safety outcomes
Compared to the no chemoprevention arm, none of the
chemoprevention arms were associated with an in-
creased risk of common adverse events of any severity
following treatment with AL (Table 5). Indeed following
treatment with AL, the risks for several common adverse
events were significantly lower in those assigned chemo-
prevention compared to those assigned no chemopre-
vention: those assigned SP had a significantly lower risk
of diarrhoea (21.3 vs 28.8%) and vomiting (9.1% vs
13.5%); those assigned TS had a significantly lower risk
of cough (43.6% vs 50.2%), diarrhoea (22.6% vs 28.8%),
and anorexia (3.7% vs 6.5%); and those assigned DP had
a significantly lower risk of diarrhoea (21.4 vs 28.8%).
There were also no significant differences in the risk of
any adverse events of severity grade 3–4 or serious ad-
verse events between any of the chemoprevention arms
and the no chemoprevention arm. Limiting the analyses
to those who were likely to be compliant with their prior
dose of DP based on a PQ level of ≥20 ng/ml, there
were no significant differences between any of the safety
outcomes compared to the no chemoprevention arm
(Table 5).
Discussion
The use of anti-malarial drugs for the prevention of mal-
aria in children at high risk has been shown to be an ef-
fective control intervention and recommended as policy
in certain epidemiological settings [1]. In two recently
published studies in HIV-unexposed and HIV-exposed
Ugandan children 6–24 months of age living in an area
of intense, year-round transmission, monthly DP was
found to be highly effective, daily TS moderately effect-
ive, and monthly SP ineffective for the prevention of
malaria [2,3]. However, in the studies the incidence of
uncomplicated malaria remained substantial even in the
setting of effective chemoprevention requiring frequent
treatment with AL, a highly effective ACT widely used
in sub-Saharan Africa. This report compares the efficacy
and safety of AL in the setting of the 3 chemopreventive
regimens described above. Initial response to AL was
Table 3 Risk factors associated with recurrent malaria within 84 days following treatment with AL
Risk factor Univariate analysis Multivariate analysis
HRa (95% CI) p-value HRa (95% CI) p-value
Chemoprevention arm No chemoprevention 1.0 (reference) - 1.0 (reference) -
Monthly SP 0.95 (0.81-1.11) 0.51 0.95 (0.81-1.12) 0.52
Daily TS 0.87 (0.72-1.05) 0.14 0.85 (0.70-1.05) 0.07
Monthly DP 0.81 (0.66-0.99) 0.04 0.77 (0.63-0.95) 0.01
Age (per 6 month increase) 1.15 (1.09-1.23) <0.001 1.19 (1.12-1.26) <0.001
Pre-treatment parasite density (per 1og10 increase) 1.06 (1.01-1.11) 0.01 1.05 (1.00-1.10) 0.04
HIV-exposure 0.91 (0.77-1.08) 0.27 0.86 (0.73-1.02) 0.09
Female gender 0.94 (0.82-1.07) 0.33 0.94 (0.82-1.07) 0.34
Urban residence 0.57 (0.27-1.20) 0.14 0.65 (0.32-1.33) 0.23
Household wealth index Lowest tertile 1.0 (reference) - 1.0 (reference) -
Middle tertile 0.92 (0.79-1.07) 0.27 0.91 (0.78-1.06) 0.24
Highest tertile 0.77 (0.65-0.91) 0.002 0.78 (0.66-0.92) 0.003
aHazard ratio adjusted for repeated measures in the same patient.
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excellent across all three chemoprevention arms; how-
ever recurrent parasitaemia and symptomatic malaria
were common within a relatively short period of time
following episodes of uncomplicated malaria. Compared
to children not assigned chemoprevention, only those
assigned chemoprevention with monthly DP had a lower
risk of recurrent malaria. In addition, evidence of better
compliance with DP based on drug levels measured at
the time malaria was associated with better protection
against subsequent episodes of malaria. There was no
evidence that any of the three chemoprevention regi-
mens was associated with an increased risk of adverse
events following treatment of uncomplicated malaria
with AL.
Data from this study comes from two parallel random-
ized control trials in young HIV-unexposed and HIV-
exposed children living in a holoendemic area where the
incidence of malaria was remarkably high despite the
provision of long-lasting ITNs to all study participants.
Although over three thousand treatments were given for
malaria, over 98% were uncomplicated cases treated with
AL. The very low rate of treatment for complicated mal-
aria seen in this study can likely be attributed to the high
quality of care and provision of prompt and effective
therapy in a research setting. AL is the recommended
first-line treatment for uncomplicated malaria in a
majority of countries in sub-Saharan Africa including
Uganda. AL has been shown to be highly effective with
PCR-corrected cure rates above 95% in the majority of
studies [8]. AL has also been shown to be safe and well-
tolerated with a safety profile comparable to other com-
monly used ACT [9]. Despite the widespread use and
excellent efficacy and safety profile of AL, there is lim-
ited data on its use in the setting of chemoprevention. In
a cluster randomized trial of seasonal malaria chemopre-
vention using SP plus amodiaquine in Senegal, treatment
of uncomplicated malaria with AL was found to be safe
and well tolerated, although results were not stratified as
Figure 3 Cumulative risk of recurrent malaria within 84 days of treatment with artemether-lumefantrine (AL) stratified by pre-treatment
piperaquine levels.
Table 4 Associations between PQ levels and risk of recurrent malaria within 84 days following treatment with AL
Risk factor Univariate analysis Multivariate analysisb
HRa (95% CI) p-value HRa (95% CI) p-value
PQ level (ng/ml) at the time malaria diagnosed <2.5c (n = 150) 1.0 (reference) - 1.0 (reference) -
2.5 - < 10 (n = 67) 0.80 (0.54-1.17) 0.25 0.83 (0.56-1.24) 0.37
10 - < 20 (n = 101) 0.65 (0.47-0.89) 0.008 0.67 (0.49-0.93) 0.02
20 - < 50 (n = 82) 0.50 (0.35-0.72) <0.001 0.51 (0.36-0.73) <0.001
≥50 (n = 25) 0.27 (0.13-0.54) <0.001 0.30 (0.14-0.63) 0.001
aHazard ratio adjusted for repeated measures in the same patient.
bcontrolling for age, pre-treatment parasite density, HIV-exposure, location of residence, household wealth index.
cBelow the limits of detection.
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to whether children treated with AL were exposed to
chemopreventive drugs [10]. As the use of anti-malarial
drugs for chemoprevention is being increasingly advo-
cated for in certain epidemiological settings and being
evaluated in others, more data is needed to evaluate the
efficacy and safety of anti-malarial drugs used for treat-
ment when other drugs are being used concomitantly
for prevention.
In this study, initial response to AL therapy for un-
complicated malaria was excellent, with rapid clearance
of fever and parasitaemia, consistent with other studies
from Uganda [11,12]. Despite rapid clearance of parasit-
aemia, the risk of recurrent parasitaemia within 28 days
was relatively high and a majority of patients developed
recurrent malaria within 84 days. Although genotyping
to distinguish recrudescence from new infections was
not performed in this study, in another study done a few
years earlier at the same study site only 1 of 200 epi-
sodes of recurrent malaria following treatment with AL
was due to recrudescence (true treatment failure) [13].
Thus it was assumed that the vast majority of episodes
of recurrent malaria following treatment with AL in this
study were due to new infections. Compared to children
not assigned chemoprevention, the risk of recurrent
malaria following treatment with AL was similar in
children assigned chemoprevention with monthly SP,
consistent with the lack of protective efficacy for this
treatment arm in the parent clinical trials [2,3]. In the
parent clinical trials, chemoprevention with daily TS
provided modest protection against malaria, however, in
this study there was only a non-significant trend towards
a lower risk of recurrent malaria following treatment
with AL compared to children assigned to no chemopre-
vention. In this study, there was no objective measure of
adherence to SP or TS, therefore one cannot rule out
non-compliance as playing a significant role in these
findings. Indeed, it is likely that children who were non-
compliant with their chemopreventive drugs would have
been at highest risk of developing malaria. In contrast,
children who were assigned monthly DP had a signifi-
cantly lower risk of developing recurrent malaria follow-
ing treatment with AL and this benefit was greatest
among children who had objective evidence of compli-
ance with their study drug based on PQ drug levels mea-
sured at the time malaria was diagnosed. These findings
suggest that chemoprevention with an effective drug like
DP may have the added benefit of reducing the risk of
recurrent malaria shortly after treatment for break-
through episodes of malaria. Indeed, evidence exists that
anti-malarial drugs with different modes of action can
profoundly influence parasite genetics and drug sensitiv-
ity. In a separate study from the same site, recent treat-
ment with AL selected for parasites with pfmdr1 alleles
associated with decreased sensitivity to lumefantrine in
subsequent episodes, while recent treatment with DP se-
lected for parasites with the opposite alleles associated
with increased sensitivity to lumefantrine [13]. This
raises the possibility that the use one ACT for chemo-
prevention and another ACT for treatment, where the
partner drugs have different modes of action, may en-
hance each other’s efficacy while reducing the risk of
propagation of drug resistant parasites.
Perhaps of equal or greater importance than the effi-
cacy of AL, is its safety and tolerability in the setting of
concomitant use of other anti-malarial drugs for chemo-
prevention. In a previous study from Uganda AL was
found to be safe and well tolerated with no increased
risk of common adverse events among HIV-infected and
HIV-exposed children who were prescribed concomitant
therapy with daily TS prophylaxis [14]. In this study
none of the chemoprevention arms were associated with
an increased risk of adverse events within 28 days of
Table 5 Safety outcomes after 28 days of follow-up
Safety outcomes Chemoprevention arm Compliant with
monthly DPa
(n = 107)
No chemoprevention
(n = 992)
Monthly SP
(n = 901)
Daily TS
(n = 721)
Monthly DP
(n = 444)
Common adverse events of any severity, n (%)
Cough 498 (50.2%) 403 (44.7%) 314 (43.6%)b 203 (47.7%) 53 (49.5%)
Elevated temperature 320 (32.3%) 259 (28.8%) 222 (30.8%) 129 (29.1%) 31 (29.0%)
Diarrhoea 286 (28.8%) 192 (21.3%)b 163 (22.6%)b 95 (21.4%)b 26 (24.3%)
Pallor 176 (17.7%) 171 (19.0%) 125 (17.3%) 61 (13.7%) 19 (17.8%)
Vomiting 134 (13.5%) 82 (9.1%)b 82 (11.4%) 45 (10.1%) 15 (14.0%)
Anorexia 64 (6.5%) 67 (7.4%) 27 (3.7%)b 30 (6.8%) 13 (12.2%)
Any grade 3–4 adverse events, n (%) 87 (8.8%) 95 (10.5%) 52 (7.2%) 38 (8.6%) 13 (12.2%)
Any serious adverse events, n (%) 20 (2.0%) 26 (2.9%) 14 (1.9%) 7 (1.6%) 2 (1.9%)
aPQ level ≥ 20 ng/ml at the time treatment with AL initiated.
bp-value < 0.05 when compared to no chemoprevention arm.
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treatment with AL compared to the no-chemoprevention
arm. Of particular concern was the administration of two
ACT regimens both containing artemisinin derivatives
(monthly DP for chemoprevention and AL for break-
through episodes of malaria). When data from this study
was limited to children with PQ levels ≥ 20 ng/ml at the
time treatment with AL was initiated (consistent with DP
being administered in the prior month), the risk of adverse
events was no different from children who were not
assigned chemoprevention. These findings are reassuring
and consistent with a recent large clinical trial conducted
in 10 countries where patients with uncomplicated falcip-
arum malaria were treated with three days of oral artesu-
nate (either 2 mg/kg or 4 mg/kg per day) followed by a
standard three-day course of an ACT (primarily AL or
DP) [15]. This prolonged course was found to be safe and
highly effective and may provide an alternative option for
treating artemisinin-resistant malaria.
There were several limitations to this study. Foremost
was the lack of directly observed therapy, as chemopre-
ventive drugs were administered at home and only the
1st of each daily dose of AL was administered in the
study clinic. Additionally, the lack of pharmacokinetic
data, with the exception of PQ levels measured at the
time malaria was diagnosed in the DP chemoprevention
arm, precluded the ability to assess drug-drug interac-
tions and their potential impact on the efficacy and
safety of AL. Study investigators, participants, and their
parents/guardians were not blinded to assigned chemo-
prevention regimens, which could have introduced bias,
especially with respect to measures of drug safety and
tolerability which were largely subjective by nature. Fi-
nally, comparisons were made between the three che-
moprevention arms and the no chemoprevention arm
for multiple efficacy and safety outcomes, resulting in
multiple tests of significance, increasing the probabil-
ity of finding significant differences just by chance.
Conclusions
In this study conducted in young children living in a
high transmission area, over 3,000 episodes of uncompli-
cated malaria were treated with AL in the setting of
three different chemopreventive regimens. AL was found
to be safe and effective, with modest protection against
recurrent episodes of malaria among children assigned
chemoprevention with monthly DP. The use of drugs for
the prevention of malaria offers great promise for high
risk populations living in Africa. However, breakthrough
episodes of malaria will inevitably occur and a better un-
derstanding of the optimal management of such episodes
in the setting of chemoprevention is needed.
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